Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 151 No. 0506 (2021)

Gestational trophoblastic disease in Switzerland: retrospective study of the impact of a regional reference centre

Cite this as:
Swiss Med Wkly. 2021;151:w20406



The European Society of Medical Oncology (ESMO) recommends that countries should have reference centres to provide adequate diagnosis and treatment of gestational trophoblastic disease. A trophoblastic disease centre in the French-speaking part of Switzerland was inaugurated in 2009. The objectives of this study were to report the activity of the centre during the last 10 years and analyse gestational trophoblastic disease outcomes.


This was a retrospective study with data collected from all cases of gestational trophoblastic disease referred to the centre from 2009 to 2018. All histological specimens as well as data for treatment and follow-up of gestational trophoblastic disease and neoplasia were reviewed. Clinical features, including age, prognostic score and International Federation of Gynecology and Obstetrics (FIGO) stages (in the case of gestational trophoblastic neoplasia), human chorionic gonadotropin (hCG) follow-up, treatment and outcome were reported.


The centre registered 354 patients, and these patients presented 156 cases of partial hydatidiform moles, 163 cases of complete hydatidiform moles and 14 cases of gestational trophoblastic neoplasia. During follow-up, 35 gestational trophoblastic neoplasms were diagnosed after hCG persistence. After pathology review, the overall agreement rates between our centre and a participating provider hospital was 82%. Methotrexate was the first line of single-agent chemotherapy for most patients, with resistance rates of 23%. Multi-agent chemotherapy was used as first-line treatment for five patients. None of the patients followed up by the centre died from gestational trophoblastic disease.


This study reflects the activity of the Swiss trophoblastic disease centre from the French-speaking part of Switzerland created in 2009, and its role as local and national reference centre, in terms of global health, for women with gestational trophoblastic disease.


  1. Horn L-C, Einenkel J, Hoehn AK. Classification and Morphology of Gestational Trophoblastic Disease. Curr Obstet Gynecol Rep. 2014;3(1):44–54. doi:.
  2. Rougemont AL, Pelte MF, Béna FS, Paoloni-Giacobino A, Petignat P, Finci V. [Trophoblastic diseases: a multidisciplinary approach, a first Swiss center]. Rev Med Suisse. 2011;7(303):1496–501. Article in French.
  3. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717–29. doi:.
  4. Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C ; ESMO Guidelines Working Group. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi39–50. doi:.
  5. Bagshawe KD, Dent J, Webb J. Hydatidiform mole in England and Wales 1973-83. Lancet. 1986;328(8508):673–7. doi:.
  6. Golfier F, Raudrant D, Frappart L, Mathian B, Guastalla JP, Trillet-Lenoir V, et al. First epidemiological data from the French Trophoblastic Disease Reference Center. Am J Obstet Gynecol. 2007;196(2):172.e1–5. doi:.
  7. Lok C, van Trommel N, Massuger L, Golfier F, Seckl M, Abreu MH, et al.; Clinical Working Party of the EOTTD. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer. 2020;130:228–40. doi:.
  8. Bolze PA, Attia J, Massardier J, Seckl MJ, Massuger L, van Trommel N, et al.; EOTTD group. Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. Eur J Cancer. 2015;51(13):1725–31. doi:.
  9. Ngan HY, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet. 2015;131(Suppl 2):S123–6. doi:.
  10. Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet. 2018;143(Suppl 2):79–85. doi:.
  11. Sita-Lumsden A, Short D, Lindsay I, Sebire NJ, Adjogatse D, Seckl MJ, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009. Br J Cancer. 2012;107(11):1810–4. doi:.
  12. Feltmate CM, Batorfi J, Fulop V, Goldstein DP, Doszpod J, Berkowitz RS. Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation. Obstet Gynecol. 2003;101(4):732–6.
  13. Golfier F, Labrousse C, Frappart L, Mathian B, Guastalla JP, Trillet-Lenoir V, et al. Évaluation de la prise en charge des tumeurs trophoblastiques gestationnelles enregistrées au Centre de référence des maladies trophoblastiques de Lyon de 1999 à 2005 [Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005]. Gynécol Obstét Fertil. 2007;35(3):205–15. Article in French. doi:.
  14. Kohorn EI. Worldwide survey of the results of treating gestational trophoblastic disease. J Reprod Med. 2014;59(3-4):145–53.
  15. Lipata F, Parkash V, Talmor M, Bell S, Chen S, Maric V, et al. Precise DNA genotyping diagnosis of hydatidiform mole. Obstet Gynecol. 2010;115(4):784–94. doi:.
  16. Lelic M, Fatusic Z, Iljazovic E, Ramic S, Markovic S, Alicelebic S. Challenges in the Routine Praxis Diagnosis of Hydatidiform Mole: a Tertiary Health Center Experience. Med Arh. 2017;71(4):256–60. doi:.
  17. Joneborg U, Marions L. Current clinical features of complete and partial hydatidiform mole in Sweden. J Reprod Med. 2014;59(1-2):51–5.
  18. Khachani I, Alami MH, Bezad R. Implementation and Monitoring of a Gestational Trophoblastic Disease Management Program in a Tertiary Hospital in Morocco: Opportunities and Challenges. Obstet Gynecol Int. 2017;2017:5093472. doi:.
  19. Sun SY, Melamed A, Joseph NT, Gockley AA, Goldstein DP, Bernstein MR, et al. Clinical Presentation of Complete Hydatidiform Mole and Partial Hydatidiform Mole at a Regional Trophoblastic Disease Center in the United States Over the Past 2 Decades. Int J Gynecol Cancer. 2016;26(2):367–70. doi:.
  20. Berkowitz RS, Goldstein DP. Clinical practice. Molar pregnancy. N Engl J Med. 2009;360(16):1639–45. doi:.
  21. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531–9. doi:.
  22. Jiao L, Ghorani E, Sebire NJ, Seckl MJ. Intraplacental choriocarcinoma: Systematic review and management guidance. Gynecol Oncol. 2016;141(3):624–31. doi:.
  23. Yarandi F, Mousavi A, Abbaslu F, Aminimoghaddam S, Nekuie S, Adabi K, et al. Five-Day Intravascular Methotrexate Versus Biweekly Actinomycin-D in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial. Int J Gynecol Cancer. 2016;26(5):971–6. doi:.
  24. Goldstein DP, Berkowitz RS, Horowitz NS. Optimal management of low-risk gestational trophoblastic neoplasia. Expert Rev Anticancer Ther. 2015;15(11):1293–304. doi:.

Most read articles by the same author(s)